<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641041</url>
  </required_header>
  <id_info>
    <org_study_id>215HV102</org_study_id>
    <secondary_id>2015-004560-11</secondary_id>
    <nct_id>NCT02641041</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants</brief_title>
  <official_title>A Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and tolerability of a single dose
      and multiple doses of BIIB033 administered to healthy adult Japanese participants. The
      secondary objectives of this study are to evaluate the pharmacokinetics (PK) profile of
      BIIB033 administered as single and multiple doses in healthy adult Japanese participants and
      to assess the single-dose and multiple-dose immunogenicity of BIIB033.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to day 113</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant laboratory parameters</measure>
    <time_frame>Up to day 113</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant vital sign abnormalities</measure>
    <time_frame>Up to day 113</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant electrocardiograms (ECGs) abnormalities</measure>
    <time_frame>Up to day 113</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant physical examination abnormalities</measure>
    <time_frame>Up to day 113</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant neurological examination abnormalities</measure>
    <time_frame>Up to day 113</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB033: Area under the concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>Up to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB033: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)</measure>
    <time_frame>Up to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB033: AUC over a given dosing interval</measure>
    <time_frame>Up to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB033: Maximum observed concentration (Cmax)</measure>
    <time_frame>Up to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB033: Time to reach maximum observed concentration (Tmax)</measure>
    <time_frame>Up to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB033: Terminal elimination half-life (t1/2)</measure>
    <time_frame>Up to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB033: Volume of distribution at steady state (Vss)</measure>
    <time_frame>Up to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB033: Clearance (CL)</measure>
    <time_frame>Up to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BIIB033: accumulation ratio (RAC)</measure>
    <time_frame>Up to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with positive serum BIIB033 antibodies</measure>
    <time_frame>Up to day 113</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Central Nervous System (CNS) Demyelinating Disease</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single IV dose of 10 mg/kg BIIB033 or placebo given on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single IV dose of 30 mg/kg BIIB033 or placebo given on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One IV dose of 100 mg/kg BIIB033 or placebo given on Days 1 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BIIB033</intervention_name>
    <description>single or multiple dose</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single or multiple dose</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Japanese subjects must have been born in Japan, and their biological parents and
             grandparents must all have been of Japanese origin.

          -  Subjects who have lived out of Japan for more than 5 years must not have significantly
             modified their diets since leaving Japan.

          -  Must be a nonsmoker or light smoker (&lt;10 cigarettes per day) and be willing to abstain
             from using tobacco and tobacco-containing products during the Inpatient Period and for
             at least 48 hours prior to Day -1, Day 14 (for Cohort 3), and all outpatient visits.

          -  Must have a body mass index of 18 to 32 kg/m2, inclusive.

        Key Exclusion Criteria:

          -  History of any clinically significant cardiac, endocrine, hematologic, hepatic,
             immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric,
             renal, or other major disease, as determined by the Investigator.

          -  Serious infection (e.g., pneumonia, septicemia) as determined by the Investigator
             within the 3 months prior to Day -1.

          -  Fever or bacterial or viral infection (including upper respiratory tract infection)
             within 2 weeks prior to Day -1.

          -  History of severe allergic or anaphylactic reactions.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese</keyword>
  <keyword>Single Ascending Dose (SAD)</keyword>
  <keyword>Multiple Ascending Dose (MAD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Demyelinating Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

